United Therapeutics Corp (UTHR) — Titan Protect Analysis

UTHR

United Therapeutics Corp

Healthcare · ·

$549.87

Data: 2026-06-03

✓ ETHICAL PASS

NARROW MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$23.2B

Total market value of the company

Trailing P/E

20.20

Premium valuation

Forward P/E

17.20

Based on estimated future earnings — lower means cheaper

Rev Growth

-1.6%

Year-over-year revenue change

Profit Margin

40.6%

How much profit the company keeps from each dollar of revenue

ROE

20.3%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$685.00

+25% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 13 analysts covering this stock

About United Therapeutics Corp

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated wit

https://www.unither.com

Country: United States Employees: 1,400 Industry: Drug Manufacturers - Specialty & Generic

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

1.021

Excellent risk-adjusted returns

Kelly Fraction

0.1069

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

1.242

Returns exceed worst-case losses — strong risk profile

Annual Return

41.0%

Historical annualised return based on price data

Max Drawdown

-33.0%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.60

Less volatile than the market — more defensive

52W High

$609.35

10% below the year high

52W Low

$272.12

102% above the year low

Avg Volume

549,461

Average daily shares traded — higher means easier to buy and sell

Short Ratio

5.4

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$27.05

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

86.6%

Revenue left after cost of goods — higher means pricing power

Operating Margin

41.7%

Profit from core operations before interest and tax

Free Cash Flow

$566M

Positive — the business generates more cash than it spends

Revenue (TTM)

$3.2B

Total revenue over the last 12 months

Net Income

$1.3B

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$750.00

Target Median

$685.00

Target Low

$516.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go